MC2149A1 - Interferons leucocytaires stabilises - Google Patents

Interferons leucocytaires stabilises

Info

Publication number
MC2149A1
MC2149A1 MC902149A MC2149A MC2149A1 MC 2149 A1 MC2149 A1 MC 2149A1 MC 902149 A MC902149 A MC 902149A MC 2149 A MC2149 A MC 2149A MC 2149 A1 MC2149 A1 MC 2149A1
Authority
MC
Monaco
Prior art keywords
alpha
volume
weight
ifn
concentration
Prior art date
Application number
MC902149A
Other languages
English (en)
French (fr)
Inventor
Ferro Alberto
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MC2149A1 publication Critical patent/MC2149A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MC902149A 1989-09-28 1990-09-24 Interferons leucocytaires stabilises MC2149A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH351489 1989-09-28

Publications (1)

Publication Number Publication Date
MC2149A1 true MC2149A1 (fr) 1992-03-10

Family

ID=4257630

Family Applications (1)

Application Number Title Priority Date Filing Date
MC902149A MC2149A1 (fr) 1989-09-28 1990-09-24 Interferons leucocytaires stabilises

Country Status (26)

Country Link
EP (1) EP0420049B1 (cs)
JP (1) JPH03130232A (cs)
KR (1) KR910005886A (cs)
CN (1) CN1050503A (cs)
AR (1) AR244551A1 (cs)
AT (1) ATE92334T1 (cs)
AU (1) AU636653B2 (cs)
CA (1) CA2024046A1 (cs)
CZ (1) CZ277712B6 (cs)
DD (1) DD298054A5 (cs)
DE (1) DE59002183D1 (cs)
FI (1) FI904756A7 (cs)
HU (1) HU205555B (cs)
IE (1) IE903479A1 (cs)
IL (1) IL95769A0 (cs)
IS (1) IS3631A7 (cs)
MC (1) MC2149A1 (cs)
MX (1) MX22522A (cs)
MY (1) MY106615A (cs)
NO (1) NO904218L (cs)
NZ (1) NZ235153A (cs)
PH (1) PH27531A (cs)
PT (1) PT95454A (cs)
RU (1) RU2008017C1 (cs)
YU (1) YU184090A (cs)
ZA (1) ZA907579B (cs)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028020A1 (en) * 1993-05-18 1994-12-08 Bukh Meditec A/S A method for the preparation of interferons
WO1997041885A1 (en) * 1996-05-09 1997-11-13 Feronpatent Limited Stabilization of interferons in aqueous solution for manufacture of sublingually administered tablets
JP2001526662A (ja) * 1997-05-09 2001-12-18 フェロンパテント リミテッド 舌下投与式タブレットの製造のための水溶液におけるインターフェロンの安定化
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
SK285284B6 (sk) * 1998-03-26 2006-10-05 Schering Corporation Vodný prostriedok umožňujúci stabilizáciu PEG-interferón alfa konjugátov, spôsob výroby lyofilizovaného prášku a výrobok s jeho obsahom
CN1175901C (zh) * 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
CA2576549C (en) 2004-08-12 2011-01-18 Schering Corporation Stable pegylated interferon formulation
DE102004048379A1 (de) 2004-10-01 2006-04-13 "Stiftung Caesar" (Center Of Advanced European Studies And Research) Federelement aus gesputterter Formgedächtnis-Legierung
CU23432B6 (es) * 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5821691A (ja) * 1981-07-29 1983-02-08 Mochida Pharmaceut Co Ltd α−及びβ−インタ−フェロンの精製方法
EP0080879B1 (en) * 1981-11-28 1986-10-01 Sunstar Kabushiki Kaisha Pharmaceutical composition containing interferon in stable state
DE3467706D1 (en) * 1983-04-28 1988-01-07 Armour Pharma Pharmaceutical preparation containing purified fibronectin
EP0133767B1 (en) * 1983-08-04 1991-04-03 The Green Cross Corporation Gamma interferon composition
NO861139L (no) * 1985-03-25 1986-09-26 Schering Corp Stabilt gamma-interferonpreparat.
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones

Also Published As

Publication number Publication date
MX22522A (es) 1993-10-01
IL95769A0 (en) 1991-06-30
EP0420049A1 (de) 1991-04-03
CZ277712B6 (en) 1993-03-17
FI904756A0 (fi) 1990-09-27
CN1050503A (zh) 1991-04-10
EP0420049B1 (de) 1993-08-04
DE59002183D1 (de) 1993-09-09
NZ235153A (en) 1993-03-26
JPH03130232A (ja) 1991-06-04
NO904218D0 (no) 1990-09-27
ZA907579B (en) 1991-06-26
KR910005886A (ko) 1991-04-27
YU184090A (sh) 1992-09-07
RU2008017C1 (ru) 1994-02-28
CS432890A3 (en) 1992-12-16
AR244551A1 (es) 1993-11-30
HUT56284A (en) 1991-08-28
DD298054A5 (de) 1992-02-06
HU205555B (en) 1992-05-28
AU636653B2 (en) 1993-05-06
FI904756A7 (fi) 1991-03-29
MY106615A (en) 1995-06-30
IS3631A7 (is) 1991-03-29
HU906021D0 (en) 1991-03-28
NO904218L (no) 1991-04-02
AU6309890A (en) 1991-04-11
IE903479A1 (en) 1991-04-10
CA2024046A1 (en) 1991-03-29
PT95454A (pt) 1991-05-22
PH27531A (en) 1993-08-18
ATE92334T1 (de) 1993-08-15

Similar Documents

Publication Publication Date Title
CN1149283C (zh) 稳定谷氨酰胺转移酶制剂及其生产方法
KR100800876B1 (ko) 면역조절제
DE69432179T3 (de) Eine formulierung des gerinnungsfaktors viii
US5744132A (en) Formulations for IL-12
KR910005888B1 (ko) 동결건조 b형 간염 왁진의 제조방법
EP0341103A1 (fr) Procédé de stabilisation des solutions d'albumine humaine et solution obtenue
JPH10500990A (ja) 各種物質の再水和または融解時の凝集を防止する方法及び該方法により得られる組成物
JPS6326120B2 (cs)
MC2149A1 (fr) Interferons leucocytaires stabilises
EP0420964A1 (en) Lyophilized peptide formulations
MC1499A1 (fr) Interferon immun humain homogene et procede pour sa preparation
EP0353150B1 (fr) IL2 humaine recombinante non glycosylée sous forme réduite, son procédé d'obtention et son application comme médicament
AP1168A (en) Stabilization of interferons in aqueous solution for manufacture of sublingually administered tablets.
KR880002037B1 (ko) 인터페론 조성물 및 이의 제조방법
JP2818834B2 (ja) ＩＬ−１α安定化医薬製剤
RU94042742A (ru) Препарат генно-инженерного гамма-интерферона
HU218103B (hu) Nem-glikozilezett, rekombináns humán interleukin-2 redukált alakját tartalmazó, stabilizált gyógyászati készítmény és eljárás előállítására
US5849282A (en) Method of treating colon, renal, and lung carcinomas with γ-interferon and Ser71 !-interleukin-1β
WO1991012316A1 (fr) Procede de preparation de derives sanguins et derives obtenus par ce procede
JP3088744B2 (ja) フィブロネクチン組成物
JPH029600B2 (cs)
AU738891B2 (en) Stable transglutaminase preparations and process for producing them
JP2587711B2 (ja) 抗腫瘍剤
JP2000509036A (ja) 安定化された抗ｂ型肝炎ワクチンタブレット
US20020114846A1 (en) Amniotic apoptosis modulating substances

Legal Events

Date Code Title Description
YP Annual fee paid